CN104257658B - 青藤碱在制备治疗慢性疼痛伴抑郁行为药物中的应用 - Google Patents
青藤碱在制备治疗慢性疼痛伴抑郁行为药物中的应用 Download PDFInfo
- Publication number
- CN104257658B CN104257658B CN201410456667.2A CN201410456667A CN104257658B CN 104257658 B CN104257658 B CN 104257658B CN 201410456667 A CN201410456667 A CN 201410456667A CN 104257658 B CN104257658 B CN 104257658B
- Authority
- CN
- China
- Prior art keywords
- sinomenine
- medicine
- chronic pain
- pain
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 title claims abstract description 91
- 229930002966 sinomenine Natural products 0.000 title claims abstract description 91
- 208000002193 Pain Diseases 0.000 title claims abstract description 63
- 208000000094 Chronic Pain Diseases 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 230000003001 depressive Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 208000004296 Neuralgia Diseases 0.000 claims abstract description 16
- 230000001684 chronic Effects 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 229940023488 Pill Drugs 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000700159 Rattus Species 0.000 abstract description 62
- 230000000202 analgesic Effects 0.000 abstract description 17
- 230000001914 calming Effects 0.000 abstract description 9
- 210000003497 Sciatic Nerve Anatomy 0.000 abstract description 5
- 208000004703 Crush Injury Diseases 0.000 abstract 1
- 230000035492 administration Effects 0.000 description 30
- 208000000114 Pain Threshold Diseases 0.000 description 28
- 230000037040 pain threshold Effects 0.000 description 28
- 230000036407 pain Effects 0.000 description 20
- 230000002980 postoperative Effects 0.000 description 9
- 230000001154 acute Effects 0.000 description 8
- 208000005298 Acute Pain Diseases 0.000 description 6
- 230000002567 autonomic Effects 0.000 description 6
- 229940079593 drugs Drugs 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000036592 analgesia Effects 0.000 description 4
- 201000008125 pain agnosia Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000003491 Skin Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003203 everyday Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003119 Arrhythmia Diseases 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 2
- 229960002327 Chloral Hydrate Drugs 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N Chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 208000010076 Mononeuropathy Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 208000000399 Procedural Pain Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000001430 anti-depressive Effects 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 238000003556 assay method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 201000005518 mononeuropathy Diseases 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229930014694 morphine Natural products 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010053552 Allodynia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000349774 Bikinia letestui Species 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 241000735235 Ligustrum vulgare Species 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 206010033775 Paraesthesia Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive Effects 0.000 description 1
- 230000000146 antalgic Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- -1 antuepileptic Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002729 catgut Substances 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000000994 depressed Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 238000010234 longitudinal analysis Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000001272 neurogenic Effects 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000000149 penetrating Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001624 sedative Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 200000000020 tissue injury Diseases 0.000 description 1
- 230000001702 transmitter Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410456667.2A CN104257658B (zh) | 2014-09-09 | 青藤碱在制备治疗慢性疼痛伴抑郁行为药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410456667.2A CN104257658B (zh) | 2014-09-09 | 青藤碱在制备治疗慢性疼痛伴抑郁行为药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104257658A CN104257658A (zh) | 2015-01-07 |
CN104257658B true CN104257658B (zh) | 2017-01-04 |
Family
ID=
Non-Patent Citations (2)
Title |
---|
疼痛和抑郁;史妙 等;《中国药物与临床》;20090930;第9卷(第9期);第789-792页 * |
青藤碱对SSNI模型大鼠镇痛效应及脑内兴奋性氨基酸递质的影响;李鹏 等;《中国药理学通报》;20120918;第28卷(第10期);第1365-1369页 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gutierrez-Blanco et al. | Postoperative analgesic effects of either a constant rate infusion of fentanyl, lidocaine, ketamine, dexmedetomidine, or the combination lidocaine-ketamine-dexmedetomidine after ovariohysterectomy in dogs | |
ES2446107T3 (es) | Composiciones para uso en cirugía | |
CA2761156C (en) | Methods of preventing ischemic injury using peripheral nociceptive stimulation | |
Gianino et al. | Intrathecal drug therapy for spasticity and pain: Practical patient management | |
AU2015341458B2 (en) | Methods for treatment of cognitive decline | |
WO2012060845A1 (en) | Methods of preventing ischemic injury using peripheral nociceptive stimulation | |
Wiese et al. | Effects of acetylcholinesterase inhibition on quality of recovery from isoflurane-induced anesthesia in horses | |
Tontodonati et al. | A canine model used to simultaneously assess potential neurobehavioural and cardiovascular effects of candidate drugs | |
CN101428138A (zh) | 敬钊缨毛蜘蛛毒素提取物—敬钊毒素—v在制备镇痛药物中的应用 | |
CN104257658B (zh) | 青藤碱在制备治疗慢性疼痛伴抑郁行为药物中的应用 | |
Ding et al. | The antiallodynic action of pregabalin may depend on the suppression of spinal neuronal hyperexcitability in rats with spared nerve injury | |
CN103254079A (zh) | 用于治疗癌性疼痛的化合物 | |
CN104257658A (zh) | 青藤碱在制备治疗慢性疼痛伴抑郁行为药物中的应用 | |
Gharbawie et al. | Cholinergic and serotonergic neocortical projection lesions given singly or in combination cause only mild impairments on tests of skilled movement in rats: evaluation of a model of dementia | |
Gulia et al. | The septal area, site for the central regulation of penile erection during waking and rapid eye movement sleep in rats: a stimulation study | |
Poon et al. | Catheterization of the thoracic spinal subarachnoid space in mice | |
CN103908567A (zh) | 一种用于治疗糖尿病痛性神经病变的复方制剂及其应用 | |
US9192602B2 (en) | Indication of anthra[2,1,c][1,2,5]thiadiazole-6,11-dione compound in alleviating pain | |
Leppert et al. | Diagnostic and therapeutic management of cancer patients with pain: recommendations of the Expert Group of the Polish Association for Palliative Care, Polish Association for the Study of Pain, and Polish Association of Clinical Oncology | |
CN103721243A (zh) | 一种生物活性多肽在制备镇痛药物中的应用方法 | |
Jain et al. | Comparison between dexmedetomidine and clonidine as an adjuvant to spinal anesthesia in abdominal hysterectomy | |
CN105412110B (zh) | 奈妥匹坦和帕洛诺司琼的治疗性组合 | |
RU2459642C2 (ru) | Способ лечения травматических невропатий | |
CN107281183B (zh) | 一种镇痛药物组合物 | |
CN106727536B (zh) | LIM激酶抑制剂LIMKi3在制备治疗疼痛药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201015 Address after: 226019 No.205, building 6, Nantong University, No.9, Siyuan Road, Nantong City, Jiangsu Province Patentee after: Center for technology transfer, Nantong University Address before: 226019 Jiangsu city of Nantong province sik Road No. 9 Patentee before: NANTONG University |
|
TR01 | Transfer of patent right |
Effective date of registration: 20201216 Address after: 215400 biomedical industry park, Shaxi Town, Taicang City, Suzhou City, Jiangsu Province Patentee after: Suzhou kangchun Pharmaceutical Technology Co.,Ltd. Address before: 226019 No.205, building 6, Nantong University, No.9, Siyuan Road, Nantong City, Jiangsu Province Patentee before: Center for technology transfer, Nantong University |